Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 17
Figure 5. Asia Pacific AI in Drug Discovery Market, 2019-2026, $ mn 20
Figure 6. Primary Drivers and Impact Factors of Asia Pacific AI in Drug Discovery Market 22
Figure 7. Primary Restraints and Impact Factors of Asia Pacific AI in Drug Discovery Market 25
Figure 8. Investment Opportunity Analysis 29
Figure 9. Porter’s Fiver Forces Analysis of Asia Pacific AI in Drug Discovery Market 32
Figure 10. Breakdown of Asia Pacific AI in Drug Discovery Market by Offering, 2019-2026, % of Revenue 36
Figure 11. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Offering, Value ($ mn) and Share (%) 37
Figure 12. Asia Pacific AI in Drug Discovery Market: Software, 2015-2026, $ mn 38
Figure 13. Asia Pacific AI in Drug Discovery Market: Service, 2015-2026, $ mn 39
Figure 14. Breakdown of Asia Pacific AI in Drug Discovery Market by Technology, 2019-2026, % of Revenue 40
Figure 15. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Technology, Value ($ mn) and Share (%) 41
Figure 16. Asia Pacific AI in Drug Discovery Market: Deep Learning, 2015-2026, $ mn 42
Figure 17. Asia Pacific AI in Drug Discovery Market: Supervised Learning, 2015-2026, $ mn 43
Figure 18. Asia Pacific AI in Drug Discovery Market: Reinforcement Learning, 2015-2026, $ mn 44
Figure 19. Asia Pacific AI in Drug Discovery Market: Unsupervised Learning, 2015-2026, $ mn 45
Figure 20. Asia Pacific AI in Drug Discovery Market: Other Technologies, 2015-2026, $ mn 46
Figure 21. Breakdown of Asia Pacific AI in Drug Discovery Market by Drug Type, 2019-2026, % of Revenue 47
Figure 22. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Drug Type, Value ($ mn) and Share (%) 48
Figure 23. Asia Pacific AI in Drug Discovery Market: Large-molecule Drugs, 2015-2026, $ mn 49
Figure 24. Asia Pacific AI in Drug Discovery Market: Small-molecular Drugs, 2015-2026, $ mn 50
Figure 25. Breakdown of Asia Pacific AI in Drug Discovery Market by Therapeutic Area, 2019-2026, % of Revenue 51
Figure 26. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Therapeutic Area, Value ($ mn) and Share (%) 52
Figure 27. Asia Pacific AI in Drug Discovery Market: Oncology, 2015-2026, $ mn 54
Figure 28. Asia Pacific AI in Drug Discovery Market: Neurodegenerative Diseases, 2015-2026, $ mn 55
Figure 29. Asia Pacific AI in Drug Discovery Market: Cardiovascular Disease, 2015-2026, $ mn 56
Figure 30. Asia Pacific AI in Drug Discovery Market: Metabolic Diseases, 2015-2026, $ mn 57
Figure 31. Asia Pacific AI in Drug Discovery Market: Other Therapeutic Areas, 2015-2026, $ mn 58
Figure 32. Breakdown of Asia Pacific AI in Drug Discovery Market by Application, 2019-2026, % of Revenue 59
Figure 33. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Application, Value ($ mn) and Share (%) 60
Figure 34. Asia Pacific AI in Drug Discovery Market: Information & Data Analysis, 2015-2026, $ mn 61
Figure 35. Asia Pacific AI in Drug Discovery Market: Drug Design, 2015-2026, $ mn 62
Figure 36. Asia Pacific AI in Drug Discovery Market: Drug Evaluation, 2015-2026, $ mn 63
Figure 37. Asia Pacific AI in Drug Discovery Market: Clinical Trials, 2015-2026, $ mn 64
Figure 38. Asia Pacific AI in Drug Discovery Market: Other Applications, 2015-2026, $ mn 65
Figure 39. Breakdown of Asia Pacific AI in Drug Discovery Market by End User, 2019-2026, % of Revenue 66
Figure 40. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by End User, Value ($ mn) and Share (%) 67
Figure 41. Asia Pacific AI in Drug Discovery Market: Pharmaceutical & Biotechnology Companies, 2015-2026, $ mn 68
Figure 42. Asia Pacific AI in Drug Discovery Market: Academic & Research Institutes, 2015-2026, $ mn 69
Figure 43. Asia Pacific AI in Drug Discovery Market: Contract Research Organizations, 2015-2026, $ mn 70
Figure 44. Breakdown of APAC AI in Drug Discovery Market by Country, 2019 and 2026, % of Revenue 72
Figure 45. Contribution to APAC 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 73
Figure 46. AI in Drug Discovery Market in China, 2015-2026, $ mn 74
Figure 47. AI in Drug Discovery Market in Japan, 2015-2026, $ mn 77
Figure 48. AI in Drug Discovery Market in India, 2015-2026, $ mn 79
Figure 49. AI in Drug Discovery Market in Australia, 2015-2026, $ mn 81
Figure 50. AI in Drug Discovery Market in South Korea, 2015-2026, $ mn 83
Figure 51. AI in Drug Discovery Market in Rest of APAC, 2015-2026, $ mn 85
Figure 52. Growth Stage of Asia Pacific AI in Drug Discovery Industry over the Forecast Period 87
Figure 53. Share of Developments of Key Vendors by Strategy Type, 2015-2019 89
Asia Pacific artificial intelligence (AI) in drug discovery will grow by 33.2% over 2020-2026 with a total addressable market cap of $2.78 billion owing to fast adoption of AI technology in pharmaceutical industry and drug development. Highlighted with 34 tables and 53 figures, this 121-page report “Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific AI in drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report provides historical market data for 2015-2019, revenue estimates for 2020, and forecasts from 2021 till 2026. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific AI in drug discovery market in every aspect of the classification from perspectives of Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country. Based on offering, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Software • Service Based on technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Deep Learning • Supervised Learning • Reinforcement Learning • Unsupervised Learning • Other Technologies Based on drug type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Large-molecule Drugs • Small-molecular Drugs Based on therapeutic area, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Oncology • Neurodegenerative Diseases • Cardiovascular Disease • Metabolic Diseases • Other Therapeutic Areas Based on application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Information & Data Analysis • Drug Design • Drug Evaluation • Clinical Trials • Other Applications Based on end user, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Pharmaceutical & Biotechnology Companies • Academic & Research Institutes • Contract Research Organizations Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each of the aforementioned countries, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Technology, Therapeutic Area, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific AI in drug discovery market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Atomwise, Inc. BenevolentAI Berg LLC Bioage BIOAGE Cloud Pharmaceuticals, Inc. Cyclica Deep Genomics Envisagenics Exscientia Google IBM Corporation Insilico Medicine Microsoft Corporation Numedii, Inc. Numerate NVIDIA Corporation Owkin, Inc. Twoxar, Incorporated Verge Genomics Xtalpi, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More